期刊
EUROPEAN UROLOGY ONCOLOGY
卷 1, 期 1, 页码 71-77出版社
ELSEVIER
DOI: 10.1016/j.euo.2018.02.006
关键词
Prostate cancer; PTEN; ERG; Docetaxel
资金
- Prostate Cancer UK
- Movember Foundation
- Royal Marsden [CEO013-2-002]
- Experimental Cancer Medical Centre from Cancer Research UK
- Department of Health [C12540/A25128]
- Cancer Research UK (Centre Programme Grant)
- MRC [MR/M018318/1] Funding Source: UKRI
Background: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensitivity remains uncertain. Objective: To study the antitumor activity of docetaxel in metastatic CRPC in relation to PTEN and ERG aberrations. Design, setting, and participants: Single-centre, retrospective analysis of PTEN loss and ERG expression using a previously described immunohistochemistry (IHC) binary classification system. Patients received docetaxel between January 1, 2006 and July 31, 2016. Outcome measurements and statistical analysis: Response correlations were analyzed using Pearson's chi(2) tests and independent-sample t tests. Overall (OS) and progressionfree survival (PFS) were analyzed using univariate and multivariate (MVA) Cox regression and Kaplan-Meier methods. Results and limitations: Overall, 215 patients were eligible. Established metastatic CRPC prognostic factors were well balanced between PTEN loss (39%) and normal patients (61%). PTEN loss was associated with shorter median OS (25.4 vs 34.7 mo; hazard ratio [HR] 1.66, 95% confidence interval [CI] 1.18-2.13; p = 0.001). There were no differences in median PFS (8.0 vs 9.1 mo; univariate HR 1.20, 95% CI 0.86-1.68; p = 0.28) and PSA response (53.4% vs 50.6%; p = 0.74). PTEN loss was an independent prognostics factor in MVA. ERG status was available for 100 patients. ERG positivity was not associated with OS or PFS. Limitations include the retrospective nature and the single-centre analysis. Conclusions: Our findings suggest that metastatic CRPC with PTEN loss might benefit more from docetaxel than from NGHT. Patient summary: In this study we found that metastatic prostate cancer with loss of the PTEN switch may benefit more from docetaxel than from abiraterone. (C) 2018 European Association of Urology. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据